Komori
Immuno-Biological Laboratories (4570) · InitiativeFirst stated

Commercialization and Sale of the AIM Measurement Kit as a Research-Use Reagent

First written in FY2018-Q2. . Latest entry: FY2018-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Commercialization and Sale of the AIM Measurement Kit as a Research-Use ReagentA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2018-Q2First statedAnnual report

    「Having obtained a license from TG, the company is proceeding with the commercialization of an AIM (apoptosis inhibitor of macrophage) assay kit as a research reagent. AIM is a protein attracting attention as a biomarker for obesity, fatty liver, other liver disorders and acute renal failure. The company aims to begin sales of the product during the current fiscal year.」

    The company is proceeding with the commercialization of the AIM assay kit, for which it obtained a license from TG, as a research reagent, and aims to begin sales during the current fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Commercialization and Sale of the AIM Measurement Kit as a Research-Use Reagent | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori